Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation

From General Health Awareness to Targeted Exposure Concerns

For decades, public health communication has centered on general wellness and disease prevention, with a strong emphasis on skin health as part of anti-aging and longevity. This legacy context has traditionally focused on lifestyle factors, nutrition, and broad environmental influences, providing a foundation for understanding how external exposures can affect long-term health outcomes. Within this framework, the role of pharmaceutical and occupational exposures has received comparatively less attention in mainstream health discourse. Recent shifts in clinical and epidemiological inquiry have begun to bridge this gap, particularly regarding immune-modulating therapies and their potential long-term consequences. Avelumab, a monoclonal antibody used in oncology, has been studied for its association with Merkel cell carcinoma risk, raising questions about the broader implications of immune checkpoint inhibition. This transition from general health education to specific exposure concerns requires careful consideration of how therapeutic agents may influence cancer susceptibility in both patient and occupational settings. The occupational dimension emerges when considering healthcare workers, researchers, and manufacturing personnel who may encounter avelumab during production or administration. Understanding the transition from general health awareness to targeted exposure risk assessment is essential for developing appropriate safety protocols and monitoring strategies in environments where such agents are handled.

Bridging General Health Education with Avelumab-Specific Evidence

Building on the legacy of general health and science information, this section transitions to the specific evidence regarding avelumab and Merkel cell carcinoma (MCC). Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Treatment Landscape

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), are currently approved by the U.S. Food and Drug Administration for the treatment of advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). These agents offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Evidence on Avelumab and MCC: Causation vs. Treatment

From a causation perspective, the relationship between avelumab and Merkel cell carcinoma is not one of causation but rather of treatment. Avelumab is indicated for the treatment of MCC, not as a cause of the disease. The evidence shows that avelumab is used to treat MCC, and that some patients may not respond or may experience disease progression while on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between exposure to avelumab and documented harm, such as disease progression or immune-related adverse events, is variable and depends on individual patient factors. The adequacy of warnings regarding avelumab and MCC is reflected in the product labeling and clinical guidelines, which note that avelumab is approved for use in metastatic MCC and that approximately 50% of patients may not respond or may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For affected patients, considerations include the potential for avelumab-refractory disease and the availability of alternative treatments such as combined ipilimumab and nivolumab, which have shown activity in some patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab and later treated with combined ipilimumab and nivolumab were collected and evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/). Three out of five patients investigated responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further confirmed these findings (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Summary and Implications for Patients and Healthcare Workers

In summary, avelumab is an established treatment for metastatic MCC, with evidence of efficacy in a subset of patients. However, a significant proportion of patients do not respond or develop resistance, highlighting the need for ongoing research into alternative therapeutic strategies. The evidence does not support a causal link between avelumab and the development of MCC; rather, avelumab is used to manage the disease. For healthcare workers and others with occupational exposure, standard precautions for handling monoclonal antibodies should be followed. Patients undergoing avelumab therapy should be monitored for disease progression and immune-related adverse events. References: https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is used to treat Merkel cell carcinoma (MCC), not cause it. Studies show that avelumab is an immune checkpoint inhibitor approved for metastatic MCC, and it works by targeting PD-L1 to help the immune system fight cancer cells. There is no evidence that avelumab causes MCC; rather, it is a therapeutic agent for the disease (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the risks of avelumab treatment for Merkel cell carcinoma?

Approximately 50% of patients with advanced MCC treated with avelumab may not respond or may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, immune-related adverse events can occur. For patients who are refractory to avelumab, alternative treatments like combined ipilimumab and nivolumab have shown activity in some cases (https://pubmed.ncbi.nlm.nih.gov/33439294/).

What is the success rate of avelumab for Merkel cell carcinoma?

In the JAVELIN Merkel 200 trial, approximately one-third of patients with chemotherapy-refractory metastatic MCC achieved confirmed objective responses with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Response rates to PD-1/PD-L1 inhibition in metastatic MCC can be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.